DUBLIN–(BUSINESS WIRE)–The “Ophthalmic Drugs Market Report 2025-2035” has been added to ResearchAndMarkets.com’s offering. World revenue for the ophthalmic drugs market, in terms of value, is forecast to surpass US$35 billion in 2025, with strong rev…
Author: Business Wire
Ophthalmic Drugs Global Market Outlook 2025-2035: Ophthalmic Drugs to Surpass $35 Billion by 2025, Paving Way for Next-Gen Eye Therapeutics – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ophthalmic Drugs Market Report 2025-2035” has been added to ResearchAndMarkets.com’s offering. World revenue for the ophthalmic drugs market, in terms of value, is forecast to surpass US$35 billion in 2025, with strong rev…
National Vision Announces Leadership Changes
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) today announced updates to its leadership structure that include expanded responsibilities for three executive team members and that Melissa…
Inflammasome Therapeutics Announces Topline 3-month Data from a Clinical Trial of its First-in-Class Dual Inflammasome Inhibitor, K8, in Geographic Atrophy, Demonstrating Rapid, Substantial and Significant Efficacy and Safety
NEWTON, Mass.–(BUSINESS WIRE)– #NRTIs–First-in-class dual inflammasome inhibitor demonstrates rapid, substantial and significant efficacy, and safety in 3 mo. trial in geographic atrophy
GenSight Biologics Announces Publication of 5-Year Outcomes for Patients Treated Unilaterally with LUMEVOQ® Gene Therapy
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced severa…
Orthobond Delivers Its First OSTAGUARD™ Coated Implants for Surgery
PRINCETON, N.J.–(BUSINESS WIRE)–Orthobond Corporation, a leader in covalently-bound antibacterial surface technologies with broad applications in the medical device industry, today announced the successful in-house production and commercial delivery …
Samsara Vision Announces Positive Six-Month Visual and Safety Outcomes from the SING IMT® (Smaller-Incision New-Generation Implantable Miniature Telescope)
FAR HILLS, N.J.–(BUSINESS WIRE)– #AMD–Samsara Vision Announces Positive 6-Mo Visual & Safety Outcomes from the SING IMT® (Smaller-Incision New-Generation Implantable Miniature Telescope)
STAAR Surgical to Host Fourth Quarter and Fiscal Year 2024 Earnings Conference Call and Webcast on February 19, 2025
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results f…
Bausch + Lomb Bolsters Pipeline with Acquisition of Whitecap Biosciences
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced an affiliate has acquired Whitecap Biosciences, LLC, which is curr…
Bausch + Lomb Launches enVista Aspire™ Intermediate Optimized Monofocal and Toric Intraocular Lenses in the European Union
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the commercial launch of the enVista Aspire monofocal and toric in…
Character Biosciences Announces Collaboration with Bausch + Lomb to Transform Ophthalmology with Precision Medicine
JERSEY CITY, N.J.–(BUSINESS WIRE)–Character Biosciences, a pioneer in genetics-guided drug discovery and development, today announced a collaboration with Bausch + Lomb, a leading global eye health company, to develop innovative treatments for patien…
Institute of Molecular and Clinical Ophthalmology Basel Spinout RhyGaze Closes USD 86 Million Series A Round to Further Novel Gene Therapy for Vision Restoration
BASEL, Switzerland & PHILADELPHIA–(BUSINESS WIRE)–RhyGaze, a biotechnology company based in Basel, Switzerland and Philadelphia, Pa., USA, today announced that it has secured a Series A financing of USD 86 million. The round was led by GV (Google Ven…
City Therapeutics Announces Strategic Collaboration with Bausch + Lomb to Develop a Novel RNAi-Based Treatment for Geographic Atrophy
CAMBRIDGE, Mass.–(BUSINESS WIRE)–City Therapeutics, Inc., a privately held biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, today announced that it has entered into a strategic collaboration with global eye heal…
Tenpoint Therapeutics Announces Positive Topline Data from Phase 3 Pivotal Study, BRIO-II, of BRIMOCHOL™ PF for the Treatment of Presbyopia
LONDON–(BUSINESS WIRE)–Tenpoint Therapeutics, Inc., a global, clinical-stage biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye, today reported positive topline results from BRIO-II, the company’s second Phase …
FDA Clears Epithelial Thickness Module for Heidelberg Engineering’s ANTERION® Multidisciplinary Imaging Platform, Advancing Precision in Corneal Health Assessment
FRANKLIN, Mass.–(BUSINESS WIRE)–Heidelberg Engineering, a global leader in ophthalmic imaging and healthcare data solutions, is pleased to announce FDA clearance of the Epithelial Thickness Module, available exclusively through the ANTERION Cornea Ap…
Outcome Capital Congratulates Elios Vision on the Acquisition by Bausch + Lomb
BOSTON–(BUSINESS WIRE)–Outcome’s expertise in corporate strategy, financing, and transaction execution helped position ELIOS as a key innovator in glaucoma treatment market
EV Group successfully finalises an investment in Cornelius Group plc through a minority equity stake.
RHO, Italy–(BUSINESS WIRE)– #Chemicals–EV Group, a leading specialty chemicals and food ingredients distributor and manufacturer, and Cornelius Group (Cornelius), an international manufacturer and distributor of specialty additives and ingredients t…
Retinal Gene Therapy Market Report 2024-2034: Limited Treatment Reach and High Cost Likely to Hamper Industry Growth – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Retinal Gene Therapy Market Report 2024-2034” report has been added to ResearchAndMarkets.com’s offering. Overall world revenue for the Retinal Gene Therapy Market will surpass US$110.0 million in 2024 This report will pro…
Biotech Showcase™ Sets the Stage for Industry Transformation in 2025
SAN FRANCISCO–(BUSINESS WIRE)– #BiotechShowcase–Biotech Showcase™ Sets the Stage for Industry Transformation in 2025